‘Biosimilar’ development takes largest portion in pharmaceutical R&D expensess

Published: 2016-03-23 16:04:00

Updated: 2016-03-23 16:04:00

A field with the largest pharmaceutical R&D expenses was turned out to be the biosimilar field.

The Korea Health Industry Development Institute announced through the recent ‘2014 Pharmaceutical Product/Medical Device R&D Status’ that the biosimilar field had the largest portion in the entire R&D expenses for finished drugs.

According to the R&D expenses by research field in the report, R&D ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.